Assessment of Adiponectin and Leptin Levels in Diabetic Patients with Varying Stages of Nephropathy
Main Article Content
Keywords
Adiponectin, Leptin, Diabetic Nephropathy, Type 2 Diabetes Mellitus, Biomarkers
Abstract
Background:
Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes mellitus, representing a leading cause of end-stage renal disease (ESRD) worldwide. Among the multiple pathogenic mechanisms implicated, adipocytokines particularly adiponectin and leptin—play a crucial role in glucose homeostasis, insulin sensitivity, inflammation, and renal function regulation. Altered levels of these adipokines have been observed in diabetic patients, yet their correlation with the progression of nephropathy remains an area of ongoing investigation. Understanding these associations could help in early detection and risk stratification of DN.
Objective:
To assess serum levels of adiponectin and leptin in diabetic patients with varying stages of nephropathy and to determine their relationship with renal function indicators, including urinary albumin excretion and estimated glomerular filtration rate (eGFR).
Methodology:
A cross-sectional analytical study was conducted on 150 patients with type 2 diabetes mellitus at Hameed Latif Hospital Lahore, stratified into three groups based on urinary albumin excretion: normoalbuminuria, microalbuminuria, and macroalbuminuria (50 patients in each group). Serum adiponectin and leptin levels were measured using enzyme-linked immunosorbent assay (ELISA). Renal function was evaluated using serum creatinine, eGFR, and urinary albumin-to-creatinine ratio (UACR). Statistical analysis was performed using ANOVA and Pearson’s correlation coefficient to assess differences and associations among variables, with p < 0.05 considered significant.
Results:
Adiponectin levels showed a significant decrease with the progression of nephropathy, while leptin levels exhibited a marked increase from normoalbuminuric to macroalbuminuric groups (p < 0.001). In patients with advanced nephropathy, serum leptin positively correlated with serum creatinine and UACR (r = 0.62 and r = 0.57, respectively), while adiponectin demonstrated a negative correlation with both parameters (r = –0.49 and r = –0.46, respectively). The adiponectin-to-leptin ratio declined progressively with increasing severity of nephropathy, indicating a potential role as an early biomarker of renal dysfunction in diabetes.
Conclusion:
The study highlights that decreased adiponectin and elevated leptin levels are closely associated with worsening renal function in diabetic nephropathy. These adipokines may serve as potential biomarkers for early detection and monitoring of nephropathy progression among diabetic patients.
References
2. Boniecka I, Jeznach-Steinhagen A, Michalska W, Rymarz A, Szostak-Węgierek D, Niemczyk S. Nutritional status, selected nutrients intake and their relationship with the concentration of ghrelin and adiponectin in patients with diabetic nephropathy. Nutrients. 2021;13(12):4416.
3. Dighe S, Ahlawat RS, Sharma D, Tyagi B, Chandrakar M. ADIPONECTIN AND LEPTIN LEVELS IN PRE-DIALYSIS PATIENTS OF CHRONIC KIDNEY DISEASE AND IT’S CORRELATION WITH Egfr. Int J Acad Med Pharm. 2025;7(3):1061-5.
4. Murtadha NA, Sarhat ER, Salih AA. Evaluation of serum adiponectin and lipid profile in regular hemodialysis patients. Int J Special Education. 2022;37(3):10808-15.
5. Kim JH, Han JM, Kim H, Lee K-B, Chung W, Kim Y-S, et al. Low serum adiponectin level is associated with better physical health-related quality of life in chronic kidney disease. Scientific Reports. 2021;11(1):10928.
6. Saha S, Hossain MS, Mekhola MH, Malakar M, Ferdous R, Kibria G, et al. Association between Serum Adiponectin level with Serum creatinine, eGFR, Lipid profile and Blood pressure in patients with Chronic Kidney disease. Mainamoti Medical College, Cumilla.3.
7. Mantovani A, Zusi C, Csermely A, Salvagno GL, Colecchia A, Lippi G, et al. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study. Hormones. 2022;21(3):477-86.
8. Mohamed MS, Youssef TM, Abdullah EE, Ahmed AE. Correlation between adiponectin level and the degree of fibrosis in patients with non-alcoholic fatty liver disease. Egyptian Liver Journal. 2021;11(1):78.
9. Choi D, Yun T, Lee D, Koo Y, Chae Y, Yang MP, et al. Serum concentrations of leptin and adiponectin in dogs with chronic kidney disease. Journal of Veterinary Internal Medicine. 2022;36(4):1330-40.
10. Navaneethan SD, Kirwan JP, Remer EM, Schneider E, Addeman B, Arrigain S, et al. Adiposity, physical function, and their associations with insulin resistance, inflammation, and adipokines in CKD. American Journal of Kidney Diseases. 2021;77(1):44-55.
11. Ahtasham Z, Kiran PU, Mahmood T, Haria J. Association of Adiponectin and Leptin Levels in Hypertensive Patients with Various Risk Factors of Metabolic Syndrome: A Cross-Sectional Study. Frontiers in Health Informatics. 2024;13(7).
12. Hao M, Lv Y, Liu S, Guo W. The New Challenge of Obesity-Obesity-Associated Nephropathy. Diabetes, Metabolic Syndrome and Obesity. 2024:1957-71.
13. Karlovich N, Mokhort Т, Sazonоva Е. Leptin and adiponectin in patients with chronic kidney disease and secondary hyperparathyroidism. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine). 2021;17(8):596-603.
14. Liao P-J, Ting M-K, Wu I-W, Chen S-W, Yang N-I, Hsu K-H. Higher leptin-to-adiponectin ratio strengthens the association between body measurements and occurrence of type 2 diabetes mellitus. Frontiers in public health. 2021;9:678681.
15. Qin Z, Yang Q, Yang M, Han M, Xiong Y, Liao R, et al. Serum leptin concentration can predict cardiovascular outcomes and all-cause death in maintenance hemodialysis patients. Clinica Chimica Acta. 2021;520:87-94.
16. Tariq F, Khan J, Abid M, Hussain TIB. Association of Serum Adiponectin and Leptin Levels with Glycemic Control in Type 2 Diabetes Mellitus. International Journal of Pharmacy Research & Technology (IJPRT). 2025;15(2):60-6.